News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Astellas Pharma Inc. Obtains China Rights to Teijin Pharma's Gout Treatment



4/2/2010 11:07:51 AM

ChinaBio Today -- Two Japanese drug companies, Teijin Pharma and Astellas, have teamed up to develop and market Teijin’s treatment for gout, TMX-67 (febuxostat), in China and Hong Kong. TMX-67 is an oral, once-daily, non-purine selective inhibitor of xanthine oxidase that is, according to Teijin, especially notable for being well-tolerated by patients with mild renal impairment. More details...

Read at ChinaBio Today

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES